Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)

About this funding opportunity

The purpose of this Notice of Funding Opportunity (NOFO) is tofurther elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART). This initiative aims to understand intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and local immune responses and the role of systemic immunity.

Topic areas: Life Sciences and Health, Social Innovation and Community Development.

Funding amount

This grant provides Up to $400K in funding, up to $400K per award.

Deadline

Applications are due Nov 05, 2028. Confirm the exact closing time on the official program page before applying.

Who can apply

This opportunity is open to the following applicant types:

• Public Authorities
• University
• SME
• NGOs
• Large Company
• Other

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs); U.S. Territory or Possession.

Agency

Early Immune System Development and Ontogeny (R01 Clinical Trial Optional) is administered by National Institutes of Health (NIH), listed via Grants.gov.